<DOC>
	<DOCNO>NCT00318422</DOCNO>
	<brief_summary>This trial conduct globally ( United States America except ) . This trial design show effect treatment liraglutide add exist glimepiride therapy compare glimepiride monotherapy rosiglitazone add-on therapy glimepiride .</brief_summary>
	<brief_title>Effect Liraglutide Blood Glucose Control Subjects With Type 2 Diabetes</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Rosiglitazone</mesh_term>
	<mesh_term>Glimepiride</mesh_term>
	<mesh_term>Liraglutide</mesh_term>
	<criteria>Type 2 diabetes Treatment oral antidiabetic drug least 3 month HbA1c : 7.011.0 % ( incl . ) subject OAD monotherapy . 7.010.0 % ( incl . ) subject OAD combination therapy Body Mass Index ( BMI ) less equal 45.0 kg/m2 . Treatment insulin within last three month Treatment drug could interfere glucose level Any serious medical condition Females pregnant , intention become pregnant breastfeeding</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>